|
1
|
Prorok PC, Wright P, Riley TR, Kramer BS,
Berg CD and Gohagan JK: Overall and multiphasic findings of the
prostate, lung, colorectal and ovarian (PLCO) randomized cancer
screening trial. Rev Recent Clin Trials. Apr 9–2018.(Epub ahead of
print). View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Devlin HL and Mudryj M: Progression of
prostate cancer: Multiple pathways to androgen independence. Cancer
Lett. 274:177–186. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Winter J, Jung S, Keller S, Gregory RI and
Diederichs S: Many roads to maturity: microRNA biogenesis pathways
and their regulation. Nat Cell Biol. 11:228–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Manikandan J, Aarthi JJ, Kumar SD and
Pushparaj PN: Oncomirs: The potential role of non-coding microRNAs
in understanding cancer. Bioinformation. 2:330–334. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang YL, Wu S, Jiang B, Yin FF, Zheng SS
and Hou SC: Role of MicroRNAs in prostate cancer pathogenesis. Clin
Genitourin Cancer. 13:261–270. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Aakula A, Kohonen P, Leivonen SK, Mäkelä
R, Hintsanen P, Mpindi JP, Martens-Uzunova E, Aittokallio T,
Jenster G, Perälä M, et al: Systematic identification of MicroRNAs
that impact on proliferation of prostate cancer cells and display
changed expression in tumor tissue. Eur Urol. 69:1120–1128. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang M, Li C, Yu B, Su L, Li J, Ju J, Yu
Y, Gu Q, Zhu Z and Liu B: Overexpressed miR-301a promotes cell
proliferation and invasion by targeting RUNX3 in gastric cancer. J
Gastroenterol. 48:1023–1033. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xu N, Shen C, Luo Y, Xia L, Xue F, Xia Q
and Zhang J: Upregulated miR-130a increases drug resistance by
regulating RUNX3 and Wnt signaling in cisplatin-treated HCC cell.
Biochem Biophys Res Commun. 425:468–472. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang Y, Lu Q and Cai X: MicroRNA-106a
induces multidrug resistance in gastric cancer by targeting RUNX3.
FEBS Lett. 587:3069–3075. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zheng Y, Wang R, Song HZ, Pan BZ, Zhang YW
and Chen LB: Epigenetic downregulation of RUNX3 by DNA methylation
induces docetaxel chemoresistance in human lung adenocarcinoma
cells by activation of the AKT pathway. Int J Biochem Cell Biol.
45:2369–2378. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Miko E, Czimmerer Z, Csanky E, Csánky E,
Boros G, Buslig J, Dezso B and Scholtz B: Differentially expressed
microRNAs in small cell lung cancer. Exp Lung Res. 35:646–664.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nakabayashi M, Hayes J, Taplin ME,
Lefebvre P, Lafeuille MH, Pomerantz M, Sweeney C, Duh MS and
Kantoff PW: Clinical predictors of survival in men with
castration-resistant prostate cancer: Evidence that Gleason score 6
cancer can evolve to lethal disease. Cancer. 119:2990–2998. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yao J, Xu C, Fang Z, Li Y, Liu H, Wang Y,
Xu C and Sun Y: Androgen receptor regulated microRNA miR-182-5p
promotes prostate cancer progression by targeting the ARRDC3/ITGB4
pathway. Biochem Biophys Res Commun. 474:213–219. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang H, Li S, Yang X, Qiao B, Zhang Z and
Xu Y: miR-539 inhibits prostate cancer progression by directly
targeting SPAG5. J Exp Clin Cancer Res. 35:602016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shi W, Gerster K, Alajez NM, Tsang J,
Waldron L, Pintilie M, Hui AB, Sykes J, P'ng C, Miller N, et al:
MicroRNA-301 mediates proliferation and invasion in human breast
cancer. Cancer Res. 71:2926–2937. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang Z, Chen G, Cheng Y, Martinka M and
Li G: Prognostic significance of RUNX3 expression in human
melanoma. Cancer. 117:2719–2727. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen F, Bai J, Li W, Mei P, Liu H, Li L,
Pan Z, Wu Y and Zheng J: RUNX3 suppresses migration, invasion and
angiogenesis of human renal cell carcinoma. PLoS One. 8:e562412013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee CW, Ito K and Ito Y: Role of RUNX3 in
bone morphogenetic protein signaling in colorectal cancer. Cancer
Res. 70:4243–4252. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen Y, Wang X, Cheng J, Wang Z, Jiang T,
Hou N, Liu N, Song T and Huang C: MicroRNA-20a-5p targets RUNX3 to
regulate proliferation and migration of human hepatocellular cancer
cells. Oncol Rep. 36:3379–3386. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wei D, Gong W, Oh SC, Li Q, Kim WD, Wang
L, Le X, Yao J, Wu TT, Huang S and Xie K: Loss of RUNX3 expression
significantly affects the clinical outcome of gastric cancer
patients and its restoration causes drastic suppression of tumor
growth and metastasis. Cancer Res. 65:4809–4816. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fukamachi H, Ito K and Ito Y:
Runx3-/-gastric epithelial cells differentiate into intestinal type
cells. Biochem Biophys Res Commun. 321:58–64. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ju X, Ishikawa TO, Naka K, Ito K, Ito Y
and Oshima M: Context-dependent activation of Wnt signaling by
tumor suppressor RUNX3 in gastric cancer cells. Cancer Sci.
105:418–424. 2014. View Article : Google Scholar : PubMed/NCBI
|
